Mike Mason, Óscar Lapuente-Santana, Anni S Halkola, Wenyu Wang, Raghvendra Mall, Xu Xiao, Jacob Kaufman, Jingxin Fu, Jacob Pfeil, Jineta Banerjee, Verena Chung, Han Chang, Scott D Chasalow, Hung Ying Lin, Rongrong Chai, Thomas Yu, Francesca Finotello, Tuomas Mirtti, Mikko I Mäyränpää, Jie Bao, Emmy W Verschuren, Eiman I Ahmed, Michele Ceccarelli, Lance D Miller, Gianni Monaco, Wouter R L Hendrickx, Shimaa Sherif, Lin Yang, Ming Tang, Shengqing Stan Gu, Wubing Zhang, Yi Zhang, Zexian Zeng, Avinash Das Sahu, Yang Liu, Wenxian Yang, Davide Bedognetti, Jing Tang, Federica Eduati, Teemu D Laajala, William J Geese, Justin Guinney, Joseph D Szustakowski, Benjamin G Vincent, David P Carbone
BACKGROUND: Predictive biomarkers of immune checkpoint inhibitor (ICI) efficacy are currently lacking for non-small cell lung cancer (NSCLC). Here, we describe the results from the Anti-PD-1 Response Prediction DREAM Challenge, a crowdsourced initiative that enabled the assessment of predictive models by using data from two randomized controlled clinical trials (RCTs) of ICIs in first-line metastatic NSCLC. METHODS: Participants developed and trained models using public resources...
February 21, 2024: Journal of Translational Medicine